Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S1, Paclitaxel, and Bevacizumab in Gastric Cancer with Malignant Ascites
NCT03990103Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Nov 2017
- Primary completion
- Apr 2021
- Modality
- Cytokines & Interferons, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, Paclitaxel Micelles for Injection in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by China Medical University. Status: unknown.
02
Drugs
bevacizumabPaclitaxel Micelles for Injection
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03990103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990103.